Humanigen Inc

Humanigen — Credit Suisse Healthcare Conference 2021

33 slides from Humanigen's conference presentation, Nov 9, 2021

  1. Slide 1: Credit Suisse Healthcare Conference November 9, 2021

    Slide 1: Credit Suisse Healthcare Conference November 9, 2021

    Credit Suisse Healthcare Conference November 9, 2021

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Slide 2: Cautionary Note Regarding Forward-Looking Statements

    2 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Cautionary Note Regarding Forward - Looking Statements All statements other than statements of historical facts contained in this presentation are forward - loo

  3. Slide 3: Company Overview

    Slide 3: Company Overview

    3 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Company Overview Leading expertise in Hyper - inflammation and Cytokine Storm across multiple therapeutic applications 520 patient Phase 3 study (‘LIVE - AIR’)

  4. Slide 4: Business Update

    Slide 4: Business Update

    4 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Business Update Lenzilumab for COVID - 19 1. September 8, 2021 FDA response to EUA submission: • Declined EUA at this time - invited Humanigen to submit additio

  5. Slide 5: Robust Clinical Pipeline

    Slide 5: Robust Clinical Pipeline

    5 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Robust Clinical Pipeline Indication Phase Status Centers Partners Lenzilumab LIVE - AIR Hospitalized COVID - 19 3 Completed (520 patients) 24 US 11 Brazil Compa

  6. Slide 6: Lenzilumab Overview

    Slide 6: Lenzilumab Overview

    6 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Lenzilumab Overview x Neutralizes GM - CSF to prevent and treat CS x Reduced immunogenicity x Highest binding affinity x Slowest off - rate Humaneered ® Best -

  7. Slide 7: LIVE-AIR Demographics and Baseline Characteristics

    Slide 7: LIVE-AIR Demographics and Baseline Characteristics

    7 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry w 7 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry LIVE - AIR Demogra

  8. Slide 8: Study Primary Endpoint Met

    Slide 8: Study Primary Endpoint Met

    8 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Study Primary Endpoint Met Kaplan - Meier Estimates For IMV and/or Death Failure to achieve survival without ventilation was defined as mortality or the require

  9. Slide 9: Baseline GM-CSF and CRP Levels Correlate with COVID-19 Disease Severity

    Slide 9: Baseline GM-CSF and CRP Levels Correlate with COVID-19 Disease Severity

    9 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Baseline GM - CSF and CRP Levels Correlate with COVID - 19 disease Severity Median CRP (mg/L) 35 85 110 205 163 0 50 100 150 200 250 HC 1/2 3 4 5 6/7 8 Baseline

  10. Slide 10: Patients With Baseline CRP<150 mg/L Required IMV Or Died Less

    Slide 10: Patients With Baseline CRP<150 mg/L Required IMV Or Died Less

    10 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Patients With Baseline CRP<150 mg/L Required IMV Or Died 4.0 29.3 0 10 20 30 40 Lenzilumab Placebo 95% CI: 15.1 - 51.9 95% CI: 0.6 - 25.2 SWOV in Black/African

  11. Slide 11: Safety Balanced Between Treatment Arms

    Slide 11: Safety Balanced Between Treatment Arms

    11 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Safety Balanced Between Treatment Arms System Organ Class Preferred Term n (%) Lenzilumab (N=255) Placebo (N=257) Overall (N=512) Any AE ≥ Grade 3 68 (26.7) 84

  12. Slide 12: ACTIV-5/BET-B Can Support EUA and BLA Submission

    Slide 12: ACTIV-5/BET-B Can Support EUA and BLA Submission

    12 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry w 12 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Humanigen believ

  13. Slide 13: ACTIV-5 Locations with Confirmed COVID Cases

    Slide 13: ACTIV-5 Locations with Confirmed COVID Cases

    13 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry ACTIV - 5 Locations with Confirmed COVID Cases (Prior 30 Days a/o 10/30/21) Recruiting Started (51) Recruiting Pending (9) Source: https://clinicaltrials.gov/c

  14. Slide 14: ACTIV-5 Locations with Confirmed COVID Cases

    Slide 14: ACTIV-5 Locations with Confirmed COVID Cases

    14 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry ACTIV - 5 Locations with Confirmed COVID Cases (Prior 30 Days a/o 10/30/21) 0 to 50 51 to 100 101 to 200 201 to 300 301 to 425 426 to 625 626 to 925 926 to 1,4

  15. Slide 15: LIVE-AIR vs ACTIV-5 Study Comparison

    Slide 15: LIVE-AIR vs ACTIV-5 Study Comparison

    15 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry w 15 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry LIVE - AIR ACTIV

  16. Slide 16: Significant Unmet Need For Hospitalized Patients

    Slide 16: Significant Unmet Need For Hospitalized Patients

    16 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry There Remains a Significant Unmet Need For Hospitalized Patients 2% OF CASES REQUIRE IMV 1,5 Critical patients in the ICU on mechanical ventilation and progres

  17. Slide 17: Lenzilumab in the United Kingdom and Rest of World

    Slide 17: Lenzilumab in the United Kingdom and Rest of World

    Lenzilumab in the United Kingdom and Rest of World

  18. Slide 18: Lenzilumab Rest of World Opportunities

    Slide 18: Lenzilumab Rest of World Opportunities

    18 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Lenzilumab Rest of World Opportunities COVID Cases Currently Approaching 245 million 1 • Ex - US countries represent 81% of cases, with 36 countries having 1 m

  19. Slide 19: European Commission Ranks Lenzilumab as One of Ten Most Promising Treatments

    Slide 19: European Commission Ranks Lenzilumab as One of Ten Most Promising Treatments

    19 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry w w 19 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry European Commi

  20. Slide 20: Multiple Agency Interactions

    Slide 20: Multiple Agency Interactions

    20 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Multiple Agency Interactions 1. https://www.gov.uk/government/collections/mhra - guidance - on - coronavirus - covid - 19 4. https://www.gov.uk/government/grou

  21. Slide 21: UK Daily Hospitalization Continue Despite ~80% Vaccination Rate

    Slide 21: UK Daily Hospitalization Continue Despite ~80% Vaccination Rate

    21 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry UK Daily Hospitalization Continue Despite ~80% Vaccination Rate Sources: Vaccinations — https://coronavirus.data.gov.uk/details/vaccinations, Hospitalization —

  22. Slide 22: Key UK Statistics

    Slide 22: Key UK Statistics

    22 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Key UK Statistics Source: https://coronavirus.data.gov.uk accessed Nov. 5, 2021 >578,642 Patients hospitalized (3/23/2020 - 11/01/2021) >141,588 Deaths within

  23. Slide 23: UK Commercial Preparation

    Slide 23: UK Commercial Preparation

    23 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry w 23 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Market research

  24. Slide 24: EMA Approval Process for COVID-19 Therapeutics

    Slide 24: EMA Approval Process for COVID-19 Therapeutics

    24 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry • Rapid review procedures established by EMA in May 2020 to provide conditional approval of medicines for COVID - 19 • Pandemic Task Force (COVID - ETF) create

  25. Slide 25: Partnered with Clinigen to Handle Managed Access Program in Europe

    Slide 25: Partnered with Clinigen to Handle Managed Access Program in Europe

    25 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry w w 25 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Partnered with

  26. Slide 26: Clinical Development Pipeline

    Slide 26: Clinical Development Pipeline

    Clinical Development Pipeline

  27. Slide 27: Opportunity to Increase Adoption of CAR-T

    Slide 27: Opportunity to Increase Adoption of CAR-T

    27 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Opportunity to Increase Adoption of CAR - T 1. https://www.marketdataforecast.com/market - reports/car - t - cell - therapy - market 2. Journal of Clinical Pat

  28. Slide 28: SHIELD Phase 3 Study of Lenzilumab + Commercially Available CAR-T

    Slide 28: SHIELD Phase 3 Study of Lenzilumab + Commercially Available CAR-T

    28 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry SHIELD Phase 3 Study of Lenzilumab + Commercially Available CAR - T 1. “Global CAR - T Therapy Market Report 2020” Research And Markets https://www.prnewswire.

  29. Slide 29: Acute GvHD: A Growing Market

    Slide 29: Acute GvHD: A Growing Market

    29 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Acute GvHD: A Growing Market 1. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2020 2. https://www.biospace.com/

  30. Slide 30: Acute Graft vs. Host Disease: Growing Market, High Unmet Need

    Slide 30: Acute Graft vs. Host Disease: Growing Market, High Unmet Need

    30 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Acute Graft vs. Host Disease ( aGvHD ): Growing Market, High Unmet Need Steroids used for initial treatment of aGvHD 2 - 6 ~50% of patients do not respond adeq

  31. Slide 31: PREACH-M Trial Phase 2/3 for CMML

    Slide 31: PREACH-M Trial Phase 2/3 for CMML

    31 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry PREACH – M Trial Phase 2/3 for CMML PREACH – M Trial — FPD October 2021 Note: CMML - Chronic Myelomonocytic Leukemia TET2, NRAS, KRAS, and CBL are gene mutatio

  32. Slide 32: Ifabotuzumab Data in GBM and Development Plan

    Slide 32: Ifabotuzumab Data in GBM and Development Plan

    32 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Phase 1 study: multiple tumors Breast Lung Colorectal Pancreas No normal tissue uptake of 89 Zr - ifabotuzumab Radio - labelled ifabotuzumab showed rapid, spec

  33. Slide 33: Short-, Medium- and Long-Term Goals

    Slide 33: Short-, Medium- and Long-Term Goals

    33 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry 12 - 15 Month Goals Initiate Phase 2/3 acute GvHD Provide additional data from ACTIV - 5/BET - B Initiate Phase 3 CAR - T SHIELD study Medium - Term Meeting wi

Source: SEC EDGAR · 8-K filed Nov 9, 2021

More decks from Humanigen Inc